Verona Pharma surges on testing news

0 mins. to read
Verona Pharma surges on testing news

AIM-listed drug developer Verona Pharma (LON:VRP) saw its shares surge 29.66% to 94p (as of 11:40 BST) after it got FDA authorisation to proceed with a clinical trial of ensifentrine in COVID-19 patients. This pilot programme will be run in addition to tests using a nebulised version of the drug to treat Chronic Obstructive Pulmonary Disease later this year.

CEO David Zaccardelli commented: “To date, the impact of COVID-19 on clinical development programs has been limited, but we continue to monitor the situation and have put in place mitigation strategies to reduce the risk of COVID-19 related delays. In March, due to the pandemic, we postponed the start of the second, multiple dose, part of the Phase 2 study with the pMDI formulation of ensifentrine in patients with moderate to severe COPD. I am pleased to report that we now plan to initiate the second part of this study in the third quarter of 2020 with results anticipated in the first half of 2021“.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *